EpiPen Price Crisis: Potential Solutions for 3.6 million Americans

“I am running a business.  I am a for-profit business.  I am not hiding from that.” That was Mylan CEO, Heather Bresch’s recent reaction to the EpiPen cost controversy. And as heartless as that may sound, she’s right. Mylan’s EpiPen essentially has no competition, and that’s why the company has been able to continuously raise…

Details